AAPL352.45+0.54 (+0.15%) ▲|ABBV286.01-6.81 (-2.33%) ▼|ABT104.48-0.23 (-0.22%) ▼|ACN227.49-11.79 (-4.93%) ▼|ADBE226.20-9.35 (-3.97%) ▼|AMAT352.30+3.07 (+0.88%) ▲|AMD530.14+26.73 (+5.31%) ▲|AMGN443.89-14.04 (-3.07%) ▼|AMT184.82+1.64 (+0.90%) ▲|AMZN267.74+9.85 (+3.82%) ▲|AVGO354.05+12.45 (+3.64%) ▲|AXP315.40-0.38 (-0.12%) ▼|BA162.91-1.00 (-0.61%) ▼|BAC48.91-0.53 (-1.07%) ▼|BKNG153.28-1.18 (-0.76%) ▼|BLK1,169.21-11.46 (-0.97%) ▼|BMY59.56-1.79 (-2.92%) ▼|BNY147.80-1.99 (-1.33%) ▼|BRK-B574.62-12.14 (-2.07%) ▼|C117.34-2.60 (-2.17%) ▼|CAT558.77-12.02 (-2.11%) ▼|CL98.85-0.76 (-0.76%) ▼|CMCSA25.24-0.07 (-0.28%) ▼|COF184.30-2.48 (-1.33%) ▼|COP134.40-5.08 (-3.64%) ▼|COST1,096.62-13.46 (-1.21%) ▼|CRM190.40-4.12 (-2.12%) ▼|CSCO97.18+2.07 (+2.18%) ▲|CVS81.35-4.46 (-5.20%) ▼|CVX205.88-8.47 (-3.95%) ▼|DE644.75-4.48 (-0.69%) ▼|DHR228.58+2.81 (+1.24%) ▲|DIS122.36+5.42 (+4.63%) ▲|DUK130.05+0.21 (+0.16%) ▲|EMR162.00+2.85 (+1.79%) ▲|FDX318.31-1.63 (-0.51%) ▼|GD349.04-6.59 (-1.85%) ▼|GE328.10+1.70 (+0.52%) ▲|GEV772.22-7.69 (-0.99%) ▼|GILD168.98-1.28 (-0.75%) ▼|GM82.13-1.92 (-2.28%) ▼|GOOG279.20+1.60 (+0.58%) ▲|GOOGL282.44+2.24 (+0.80%) ▲|GS873.18-4.34 (-0.49%) ▼|HD337.64-1.37 (-0.40%) ▼|HON222.70+3.74 (+1.71%) ▲|IBM228.53-2.56 (-1.11%) ▼|INTC54.67-0.50 (-0.91%) ▼|INTU313.24-7.55 (-2.35%) ▼|ISRG420.95-9.58 (-2.23%) ▼|JNJ272.70-6.00 (-2.15%) ▼|JPM324.11-5.85 (-1.77%) ▼|KO98.09-0.70 (-0.71%) ▼|LIN512.16-2.95 (-0.57%) ▼|LLY1,382.75-32.80 (-2.32%) ▼|LMT578.19-12.15 (-2.06%) ▼|LOW222.78+2.32 (+1.05%) ▲|LRCX211.67+0.98 (+0.47%) ▲|MA643.37-2.36 (-0.37%) ▼|MCD274.03-1.79 (-0.65%) ▼|MDLZ66.57-0.19 (-0.28%) ▼|MDT100.72-1.60 (-1.56%) ▼|META616.38-2.49 (-0.40%) ▼|MMM181.05+0.17 (+0.09%) ▲|MO76.26-1.20 (-1.55%) ▼|MRK137.78-5.59 (-3.90%) ▼|MS181.17-2.36 (-1.29%) ▼|MSFT508.29+2.05 (+0.40%) ▲|MU705.27-7.15 (-1.00%) ▼|NEE84.78+0.36 (+0.43%) ▲|NFLX59.82+0.14 (+0.23%) ▲|NKE36.31+0.46 (+1.28%) ▲|NOW90.59-2.31 (-2.49%) ▼|NVDA150.96-4.50 (-2.89%) ▼|ORCL113.89-1.11 (-0.97%) ▼|PEP141.87-0.15 (-0.11%) ▼|PFE28.06-0.41 (-1.44%) ▼|PG170.29-1.43 (-0.83%) ▼|PLTR156.67+0.11 (+0.07%) ▲|PM192.73-1.65 (-0.85%) ▼|QCOM159.81-6.86 (-4.12%) ▼|RTX197.45-0.55 (-0.28%) ▼|SBUX109.11+1.62 (+1.51%) ▲|SCHW92.56+0.72 (+0.78%) ▲|SO94.41+0.81 (+0.87%) ▲|SPG231.38+1.14 (+0.50%) ▲|T21.95-0.34 (-1.53%) ▼|TMO692.74+5.95 (+0.87%) ▲|TMUS164.02-3.88 (-2.31%) ▼|TSLA383.72+3.61 (+0.95%) ▲|TXN292.43-3.43 (-1.16%) ▼|UBER68.76-0.05 (-0.07%) ▼|UNH349.91-39.77 (-10.21%) ▼|UNP300.90+3.87 (+1.30%) ▲|UPS111.03+0.72 (+0.65%) ▲|USB58.28-0.90 (-1.52%) ▼|V415.22-1.55 (-0.37%) ▼|VZ46.13+0.20 (+0.44%) ▲|WFC80.92-1.77 (-2.14%) ▼|WMT127.36-0.16 (-0.13%) ▼|XOM160.58-6.63 (-3.97%) ▼|AAPL352.45+0.54 (+0.15%) ▲|ABBV286.01-6.81 (-2.33%) ▼|ABT104.48-0.23 (-0.22%) ▼|ACN227.49-11.79 (-4.93%) ▼|ADBE226.20-9.35 (-3.97%) ▼|AMAT352.30+3.07 (+0.88%) ▲|AMD530.14+26.73 (+5.31%) ▲|AMGN443.89-14.04 (-3.07%) ▼|AMT184.82+1.64 (+0.90%) ▲|AMZN267.74+9.85 (+3.82%) ▲|AVGO354.05+12.45 (+3.64%) ▲|AXP315.40-0.38 (-0.12%) ▼|BA162.91-1.00 (-0.61%) ▼|BAC48.91-0.53 (-1.07%) ▼|BKNG153.28-1.18 (-0.76%) ▼|BLK1,169.21-11.46 (-0.97%) ▼|BMY59.56-1.79 (-2.92%) ▼|BNY147.80-1.99 (-1.33%) ▼|BRK-B574.62-12.14 (-2.07%) ▼|C117.34-2.60 (-2.17%) ▼|CAT558.77-12.02 (-2.11%) ▼|CL98.85-0.76 (-0.76%) ▼|CMCSA25.24-0.07 (-0.28%) ▼|COF184.30-2.48 (-1.33%) ▼|COP134.40-5.08 (-3.64%) ▼|COST1,096.62-13.46 (-1.21%) ▼|CRM190.40-4.12 (-2.12%) ▼|CSCO97.18+2.07 (+2.18%) ▲|CVS81.35-4.46 (-5.20%) ▼|CVX205.88-8.47 (-3.95%) ▼|DE644.75-4.48 (-0.69%) ▼|DHR228.58+2.81 (+1.24%) ▲|DIS122.36+5.42 (+4.63%) ▲|DUK130.05+0.21 (+0.16%) ▲|EMR162.00+2.85 (+1.79%) ▲|FDX318.31-1.63 (-0.51%) ▼|GD349.04-6.59 (-1.85%) ▼|GE328.10+1.70 (+0.52%) ▲|GEV772.22-7.69 (-0.99%) ▼|GILD168.98-1.28 (-0.75%) ▼|GM82.13-1.92 (-2.28%) ▼|GOOG279.20+1.60 (+0.58%) ▲|GOOGL282.44+2.24 (+0.80%) ▲|GS873.18-4.34 (-0.49%) ▼|HD337.64-1.37 (-0.40%) ▼|HON222.70+3.74 (+1.71%) ▲|IBM228.53-2.56 (-1.11%) ▼|INTC54.67-0.50 (-0.91%) ▼|INTU313.24-7.55 (-2.35%) ▼|ISRG420.95-9.58 (-2.23%) ▼|JNJ272.70-6.00 (-2.15%) ▼|JPM324.11-5.85 (-1.77%) ▼|KO98.09-0.70 (-0.71%) ▼|LIN512.16-2.95 (-0.57%) ▼|LLY1,382.75-32.80 (-2.32%) ▼|LMT578.19-12.15 (-2.06%) ▼|LOW222.78+2.32 (+1.05%) ▲|LRCX211.67+0.98 (+0.47%) ▲|MA643.37-2.36 (-0.37%) ▼|MCD274.03-1.79 (-0.65%) ▼|MDLZ66.57-0.19 (-0.28%) ▼|MDT100.72-1.60 (-1.56%) ▼|META616.38-2.49 (-0.40%) ▼|MMM181.05+0.17 (+0.09%) ▲|MO76.26-1.20 (-1.55%) ▼|MRK137.78-5.59 (-3.90%) ▼|MS181.17-2.36 (-1.29%) ▼|MSFT508.29+2.05 (+0.40%) ▲|MU705.27-7.15 (-1.00%) ▼|NEE84.78+0.36 (+0.43%) ▲|NFLX59.82+0.14 (+0.23%) ▲|NKE36.31+0.46 (+1.28%) ▲|NOW90.59-2.31 (-2.49%) ▼|NVDA150.96-4.50 (-2.89%) ▼|ORCL113.89-1.11 (-0.97%) ▼|PEP141.87-0.15 (-0.11%) ▼|PFE28.06-0.41 (-1.44%) ▼|PG170.29-1.43 (-0.83%) ▼|PLTR156.67+0.11 (+0.07%) ▲|PM192.73-1.65 (-0.85%) ▼|QCOM159.81-6.86 (-4.12%) ▼|RTX197.45-0.55 (-0.28%) ▼|SBUX109.11+1.62 (+1.51%) ▲|SCHW92.56+0.72 (+0.78%) ▲|SO94.41+0.81 (+0.87%) ▲|SPG231.38+1.14 (+0.50%) ▲|T21.95-0.34 (-1.53%) ▼|TMO692.74+5.95 (+0.87%) ▲|TMUS164.02-3.88 (-2.31%) ▼|TSLA383.72+3.61 (+0.95%) ▲|TXN292.43-3.43 (-1.16%) ▼|UBER68.76-0.05 (-0.07%) ▼|UNH349.91-39.77 (-10.21%) ▼|UNP300.90+3.87 (+1.30%) ▲|UPS111.03+0.72 (+0.65%) ▲|USB58.28-0.90 (-1.52%) ▼|V415.22-1.55 (-0.37%) ▼|VZ46.13+0.20 (+0.44%) ▲|WFC80.92-1.77 (-2.14%) ▼|WMT127.36-0.16 (-0.13%) ▼|XOM160.58-6.63 (-3.97%) ▼|
13.4 C
New York
Thursday, November 19, 2026

Energy

DNV supports FAMID Biomedical Technology in achieving IVDR certification for its Class C IVD in six months

Certification supports European market access for a diagnostic test designed to aid the diagnosis of cervical precancerous lesions.HOVIK, Norway, Nov. 18, 2026 /PRNewswire/ -- DNV, an EU Notified Body...

DEFINITY FINANCIAL CORPORATION ANNOUNCES $500 MILLION PRIVATE PLACEMENT OF NOTES

/NOT FOR DISTRIBUTION TO THE U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED...

Harbour BioMed Announces NMPA Acceptance of IND Application for Its First AI-Enabled Drug Candidate LET003 for the Treatment of Overweight or Obesity

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Nov. 18, 2026 /PRNewswire/ -- Harbour BioMed (the "Company";...

Paras brand Wheat Free Flour recalled due to undeclared wheat

OTTAWA, ON, Nov. 18, 2026 /CNW/ -- Product: Wheat Free FlourIssue: Food - Allergen -...

Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt...

BOSTON, June 24, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray...

Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

MINNEAPOLIS, June 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company...

Abcentra Announces Appointment of Dr. Peter Libby as a Board Member as it Enters Orticumab’s Phase 2b Trial (FORTIFY)

LOS ANGELES, June 24, 2025 /PRNewswire/ -- Abcentra LLC (Abcentra), a clinical stage biotechnology company specializing in coronary artery disease, today announced the appointment...

Sterotherapeutics Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating ST-002 for Cushing’s Syndrome

DOYLESTOWN, Pa., June 24, 2025 /PRNewswire/ -- Sterotherapeutics LLC, a clinical-stage biopharmaceutical company focused on rare endocrine diseases, today announced that the first patient...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II...

Equinor ASA: Share buy-back – second tranche for 2025

Please see below information about transactions made under the second tranche of the 2025 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO).

Equinor ASA: Tilbakekjøp av egne aksjer – andre transje for 2025

Nedenfor følger informasjon om transaksjoner foretatt under andre transje av Equinor ASAs (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO) tilbakekjøpsprogram for 2025.

Trinasolar and Universidad Politécnica de Madrid Strengthen Partnership with Inauguration of Demo Center

A new space to foster collaboration, innovation, and hands-on learning in solar energy — part of Trinasolar's growing global network of university-linked Demo Centers. MADRID,...

Cielo Provides Update on Settlement Agreement, Shareholder Meeting and Webinar, and Units for Debt Transactions

Cielo Provides Update on Settlement Agreement, Shareholder Meeting and Webinar, and Units for Debt Transactions

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.